| Literature DB >> 25149181 |
Ulziijargal Gurjav, Peter Jelfs, Nadine McCallum, Ben J Marais, Vitali Sintchenko1.
Abstract
BACKGROUND: Molecular epidemiology of Mycobacterium tuberculosis, its transmission dynamics and population structure have become important determinants of targeted tuberculosis control programs. Here we describe recent changes in the distribution of M. tuberculosis genotypes in New South Wales (NSW), Australia and compared strain types with drug resistance, site of disease and demographic data.Entities:
Mesh:
Year: 2014 PMID: 25149181 PMCID: PMC4262242 DOI: 10.1186/1471-2334-14-455
Source DB: PubMed Journal: BMC Infect Dis ISSN: 1471-2334 Impact factor: 3.090
Figure 1Flow diagram of new cases with culture-confirmed complex diagnosed in NSW. *Used for population structure and clustering analysis (Table 3) **Used for demographic and drug resistance analysis (Tables 1 and 2) #Phenotypic drug susceptibility test (routinely done for INH and RIF).
Comparison of clustering based on MIRU-12 and MIRU-24 typing
| Characteristic | Dominant strain families | Total | ||||||
|---|---|---|---|---|---|---|---|---|
| Beijing | EAI** | Delhi/CAS | (N = 1128) | |||||
| (N = 309) | (N = 324) | (N = 158) | ||||||
|
|
|
|
|
|
|
|
|
|
| Number of clusters | 32 | 42 | 35 | 18 | 17 | 5 | 139 | 82 |
| Number of clustered isolates# | 249 | 125 | 190 | 44 | 69 | 12 | 695 | 227 |
| % clustering | 80.6 | 40.5 | 58.6 | 13.6 | 43.7 | 7.6 | 61.6 | 20.1 |
| Average cluster size | 8 | 3 | 5.4 | 2.4 | 4.1 | 2.8 | 5 | 2.8 |
| Transmission rate (%)## | 70.2 | 26.9 | 47.8 | 8.0 | 32.9 | 4.4 | 49.3 | 12.8 |
*MIRU - mycobacterial interspersed repetitive unit.
**EAI – East African Indian strain family (Lineage 3).
#Two or more strains with identical MIRU profiles were considered a cluster.
##Calculated as (number of clustered isolates - number of clusters)/total number of isolates.
Demographics, site of disease, strain family and drug resistance profile in new patients with culture–confirmed tuberculosis diagnosed in New South Wales, Australia
| Category | Year | Total | ||
|---|---|---|---|---|
| 2010 | 2011 | 2012 | n (%) | |
|
| ||||
| Male | 219 (61.3) | 219 (59.0) | 188 (53.6) | 626 (58.0) |
|
| ||||
| <15 years | 4 (1.1) | 5 (1.3) | 6 (1.7) | 15 (1.4) |
| 15-29 years | 99 (27.7) | 94 (25.3) | 102 (29.1) | 295 (27.3) |
| 30-44 years | 110 (30.8) | 116 (31.3) | 102 (29.1) | 328 (30.4) |
| 45-59 years | 63 (17.6) | 60 (16.2) | 48 (13.7) | 171 (15.8) |
| ≥60 years | 81 (22.7) | 96 (25.9) | 93 (26.5) | 270 (25.0) |
|
| ||||
| Respiratory | 258 (72.3) | 260 (70.1) | 241 (68.7) | 759 (70.3) |
| Non-respiratory | 99 (27.7) | 111 (29.9) | 110 (31.3) | 320 (29.7) |
|
| ||||
| Beijing | 93 (26.1) | 108 (29.1) | 97 (27.6) | 298 (27.6) |
| East African Indian | 112 (31.4) | 101 (27.2) | 95 (27.1) | 308 (28.5) |
| Delhi/CAS | 47 (13.2) | 53 (14.3) | 49 (14.0) | 149 (13.8) |
| LAM | 25 (7.0) | 14 (3.8) | 22 (6.3) | 61 (5.7) |
| Haarlem | 13 (3.6) | 21 (5.7) | 24 (6.8) | 58 (5.4) |
| Other | 67 (18.8) | 74 (19.9) | 64 (18.2) | 205 (19.0) |
|
| ||||
| Isoniazid mono-resistance | 21 (5.9) | 23 (6.2) | 29 (8.3) | 73 (6.8) |
| Multi- or extremely drug resistant (M/XDR) | 7 (2.0) | 6 (1.6) | 5 (1.4) | 18 (1.7) |
|
|
|
|
|
|
Changes in population structure and drug resistance profiles in New South Wales, Australia
| Characteristic | 2006-2008* | 2010-2012** | p-value |
|---|---|---|---|
| n (%) | n (%) | ||
|
| 855 (100) | 1079 (100) | |
|
| |||
| Beijing | 206 (24.1) | 298 (27.6) | 0.58 |
| East African Indian (EAI) | 101 (11.8) | 308 (28.5) | <0.01 |
| Delhi/CAS | 55 (6.5) | 149 (13.8) | 0.13 |
|
| |||
| Isoniazid mono-resistance | 59 (6.9) | 73 (6.8) | 1 |
| Multi-drug resistant (MDR)*** | 9 (1.1) | 18 (1.7) | 0.56 |
Notes:
*MIRU-12 typing and spoligotyping.
**MIRU-24 typing.
***Single extensively drug resistant (XDR) case detected in 2010.
Figure 2strain family and site of disease.
Figure 3Relative abundance of prevalent strain families in particular age groups.